Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Stanford University
Kura Oncology, Inc.
Augusta University
University of Nebraska
Center for International Blood and Marrow Transplant Research
Dana-Farber Cancer Institute
Takeda
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Center for International Blood and Marrow Transplant Research